Gilead Sciences
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and
Gilead Sciences
Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2, the offer has now been pushed back to April 24, 2026. This delay, while framed as a standard procedural
Gilead Sciences
In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines for approximately $2.175 billion. The deal marks Gilead’s second massive investment in the immunology sector within a
Gilead Sciences
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir, now marketed as Yeztugo. As of February 25, 2026, the biopharmaceutical giant has successfully transitioned from a provider of daily oral regimens
Gilead Sciences
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive, high-yield corridors of the healthcare sector. At the center of this movement is Gilead Sciences (Nasdaq: GILD), which has defied
Earnings Season
The second quarter 2025 earnings season has largely concluded, delivering a powerful shot of optimism to the financial markets. Against a backdrop of persistent economic uncertainties and geopolitical tensions, a surprising number of U.S. corporations have not only met but significantly exceeded analyst expectations for both earnings and revenue.
Earnings Season
The second quarter of 2025 has largely concluded as a period of unexpected strength for U.S. corporations, with a significant number of companies not only meeting but exceeding analyst expectations. This positive trend has injected a renewed sense of optimism into the financial markets, showcasing the resilience of various